|
|
Kalorama's Proteomics 50: Competing Technologies and Alliances in an Emerging IndustryPublished by: Kalorama Information Published: Nov. 1, 2001 - 268 Pages Special Offer. Now 25% off the original price of $1995.Table of Contents Chapter 1: Executive Summary
Scope and Methodology Proteomics and Genomics Proteomics and Bioinformatics Challenges Facing Proteomics Research Proteomics Technologies Proteomics Technology Applications and Potential Markets Markets for Proteomics Technologies Pharmaceutical Industry Trends Healthcare Trends Competitors in Proteomics Funding Sources for Proteomics Chapter 2: Introduction
Biological Research in the Post-Genomic Era Proteomics and Genomics Proteomics and Bioinformatics Challenges Facing Proteomics Research Chapter 3: Proteomics Technologies
Overview Principal Steps in Protein Analysis Protein Function Studies Bioinformatics Chapter 4: Technology Applications And Potential Markets
Proteomics in Perspective Proteomics Technology Applications Markets for Proteomics Technologies Competitive Landscape Funding Sources for Proteomics Chapter 5: Kalorama's Proteomics 50: Company Profiles Activx Biosciences Inc. AlphaGene Inc. Applied Biosystems Group Archemix Corporation Athersys Incorporated AxCell Biosciences Corporation Beyond Genomics Incorporated Biacore International AB Caliper Technologies Caprion Pharmaceuticals Inc. Ciphergen Biosystems, Inc. Compugen Ltd. CuraGen Corporation DoubleTwist Incorporated Exelixis Incorporated GPC Biotech AG Geneva Bioinformatics SA (GeneBio) GeneData Incorporated GeneProt Incorporated Genomic Solutions Incorporated Hybrigenics SA Incyte Genomics Incorporated Inpharmatica Ltd Integrative Proteomics, Inc. Large Scale Biology Corporation LigoCyte Pharmacuticals, Inc. LumiCyte Incorporated Lynx Therapeutics Incorporated MDS Proteomics Incorporated MediChem Life Sciences Molecular Staging Incorporated Myriad Genetics Incorporated NeoGenesis Incorporated Novalon Pharmaceutical Corporation Odyssey Pharmaceuticals Incorporated Oxford Glycosciences Pepscan Systems Phylos Incorporated Protein Pathways Incorporated Proteome Systems Limited ProteoMetrics, Inc Protiveris Incorporated Rigel Pharmaceuticals Incorporated Sense Proteomic Limited SYNX Pharma Incorporated Syrrx Incorporated WITA Proteomics AG Xencor Incorporated Xerion Pharmaceuticals GmbH Zyomyx Incorporated Appendix--Company Index List of Exhibits Table 3-1: Top Protein Separation Technologies Table 3-2: Top Protein Identification and Characterization Technologies Table 3-3: Top Protein Chip Technology Table 3-4: Top Technologies in Protein Function Studies Table 3-5: Selected Databases Available for Proteomics Research Table 4-1: Kalorama's Proteomics 50 in Collaborations with Pharmaceutical Companies Figure 3-1: Proteomics Toolbox Technologies Figure 4-1: Value of Proteomics Technologies, 2001-2006 AbstractWith the Human Genome Project in its culminating phase, scientists are turning to the task of converting the soon to be completed DNA sequence into information that will improve human medicine and health care. One of the key challenges ahead is understanding how proteins direct biological functions. Proteomics, the science of the cellular protein universe, attempts to catalog and characterize proteins, compare variations in their expression levels under different conditions (i.e., various stages of disease compared with nondisease states), study their interactions, and identify their functional roles. However, these studies will not produce a complete "proteome," or a map of an organism, because cells are always changing, as is protein expression. Scientists believe there is a powerful distinction to be made between the molecular function of an isolated protein and the function of that protein in the complex cellular environment.The goals of proteomics in medicine are to provide the ability to predict rather than confirm disease and to construct a new, systematic way to discover drugs. A preliminary step in achieving these goals requires that researchers acquire or invent the technology to fit its aspirations. Several approaches are being studied including structural genomics, a branch of proteomics, which studies the shapes of proteins with the goal of constructing a lexicon as well as an understanding of where in the body different proteins are produced, and how each is controlled. One molecular biologist, Richard Burgess of the McArdle Laboratory for Cancer Research at the University of Wisconsin, defines the scope of proteomics as "a grab bag of activities that are all in the postgenomics or functional genomics area, or the what-do-we-need-to-know-to-make-sense-of-all-the-genomics-data arena." Proteomics is not the study of proteins one by one, as has been done traditionally, but in an automated, large-scale manner that requires new technologies and techniques. Proteomics includes not only the identification and quantification of proteins, but also the determination of their localization, modifications, interactions, activities, and, ultimately, their function. Considerable effort is currently being devoted to the development of novel technologies to unravel the mystery of proteins.
Companies competing in the proteomics space offer technology platforms for discovering or screening drug candidates or diagnostic markers. One of the ways emerging proteomics companies fund their enterprises, is selling their services to the pharmaceutical industry through an wide array of alliances and collaborations. This report will examine competing technologies, and the alliances being formed in the proteomics arena today.
|
|
|||
|
About MarketResearch.com
|
||||